J
Janet E. Brown
Researcher at University of Sheffield
Publications - 174
Citations - 11034
Janet E. Brown is an academic researcher from University of Sheffield. The author has contributed to research in topics: Zoledronic acid & Breast cancer. The author has an hindex of 47, co-authored 165 publications receiving 9751 citations. Previous affiliations of Janet E. Brown include Yorkshire Cancer Research & Royal Lancaster Infirmary.
Papers
More filters
Journal ArticleDOI
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study
Karim Fizazi,Michael A. Carducci,Matthew R. Smith,Ronaldo Damião,Janet E. Brown,Lawrence Karsh,Piotr Milecki,Neal D. Shore,Michael Rader,H. Wang,Qi Jiang,Sylvia Tadros,Roger Dansey,Carsten Goessl +13 more
TL;DR: Denosumab was better than zoledronic acid for prevention of skeletal-related events, and potentially represents a novel treatment option in men with bone metastases from castration-resistant prostate cancer.
Journal ArticleDOI
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases
Fred Saad,Janet E. Brown,C. Van Poznak,Toni Ibrahim,Salomon M. Stemmer,Alison Stopeck,Ingo Diel,Shunji Takahashi,Neal D. Shore,David H. Henry,Carlos H. Barrios,T. Facon,Francis M. Senecal,Karim Fizazi,Lei Zhou,Alan H. Daniels,P. Carriere,Roger Dansey +17 more
TL;DR: In this combined analysis of three prospective trials, Osteonecrosis of the jaw was infrequent, management was mostly conservative, and healing occurred in over one-third of the patients.
Journal ArticleDOI
Bone Turnover Markers as Predictors of Skeletal Complications in Prostate Cancer, Lung Cancer, and Other Solid Tumors
Janet E. Brown,Richard J. Cook,Pierre Major,Pierre Major,Allan Lipton,Fred Saad,Matthew R. Smith,Ker-Ai Lee,Ming Zheng,Y. J. Hei,Robert E. Coleman +10 more
TL;DR: Baseline and recent bone marker levels were predictive of negative clinical outcomes in patients with bone metastases secondary to prostate cancer and to NSCLC and other solid tumors, reflecting the key role of osteolysis in the development of skeletal complications.
Journal ArticleDOI
Predictive Value of Bone Resorption and Formation Markers in Cancer Patients With Bone Metastases Receiving the Bisphosphonate Zoledronic Acid
Robert E. Coleman,Pierre Major,Allan Lipton,Janet E. Brown,Ker Ai Lee,Matthew Smith,F. Saad,Ming Zheng,Yong Jiang Hei,John W. Seaman,Richard J. Cook +10 more
TL;DR: The bone resorption marker Ntx provides valuable prognostic information in patients with bone metastases receiving bisphosphonates, and showed some correlation with risk of negative clinical outcomes.
Journal ArticleDOI
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
Allan Lipton,Karim Fizazi,Alison Stopeck,David H. Henry,Janet E. Brown,Denise A. Yardley,Gary Richardson,Salvatore Siena,Pablo Maroto,Michael Clemens,Boris Bilynskyy,Veena Charu,Philippe Beuzeboc,Michael Rader,María Viniegra,Fred Saad,Chunlei Ke,Ada Braun,Susie Jun +18 more
TL;DR: Denosumab was superior to zoledronic acid in preventing SRE with favourable safety and convenience in patients with bone metastases from advanced cancer.